About us

W
FutureLife
European Leader in Reproductive Medicine and Women’s Care

We are one of the largest and fastest-growing assisted reproduction providers in the world. Our current portfolio contains over 45 clinics in ten countries, where more than 1500 people are employed, including 450 physicians. Within the group a comprehensive treatments of fertility and sterility problems are provided, including genetic, immunological and other follow-up examinations.

Our main goal is to provide a quality care and a successful treatment amongst the group as a whole. Thanks to the continuous growth of the company, its reinvestments into existing facilities, research and education, we can ensure the highest level expertise, economic stability, high-quality conditions and a fair remuneration of our employees.

Expert
Guarantors

Simon
Fishel
Chairman of FutureLife scientific advisory board

Professor Fishel began his research in Cambridge with the late Professor Sir Robert Edwards, CBE, FRS Nobel Laureate several years before the birth of the first IVF baby in 1978. He is one of the world’s most eminent specialists in the field of fertility treatment. He is recognized for his pioneering work in embryology and IVF, received numerous international awards for his work in the field of assisted reproduction, published over 200 papers and edited 4 books on the development of IVF and micromanipulation technology. Simon Fishel is chairman of FutureLife scientific advisory board.

Paul
Serhal
Medical Director, CRGH London

Paul Serhal is an accredited consultant in Reproductive Medicine and is a Fellow of the Royal College of Obstetricians and Gynaecologists. He was a Clinical Lecturer in Obstetrics and Gynaecology at University College London Hospital. His vast experience of male and female infertility has ensured that CRGH is amongst world-class leaders in the pioneering of new techniques, such as pre-implantation genetic diagnosis and the advancement of fertility treatments. Mr Serhal has published more than 100 articles in books and journals and frequently lectures at international conferences.

Štěpán
Machač
Chief Medical Director, FutureLife

MUDr. Štěpán Machač, Ph.D. was born in 1970. He graduated from the Palacký University of Medicine in Olomouc. From 1995 – 2003 he worked at the Gynaecology and Obstetrics Clinic of Faculty of Medicine and Dentistry at Palacký University Olomouc and started to deal with infertility treatment. In 2006, he obtained a Ph.D. degree, after defending his dissertation on ovarian hyper stimulation syndrome and congenital thrombophilia. In the years 2006 – 2014, he worked at the Reprofit International clinic as the lead IVF physician for foreign patients. Since 2014 he has been acting as a head of the IVF Clinic in Olomouc. In 2018 he was appointed as a Future Life CMO.

He has authored or co-authored more than 30 lectures and 40 articles in professional journals. In his work he focuses mainly on the issue of assisted reproduction, ovarian hyperstimulation syndrome and gamma donation.

Marisa López
Teijón Pérez
CEO, Institut Marquès

Director of Institut Marquès since the 2000’s, she´s member of the Governing Board of Sterility and Infertility Section of the Spanish Society for Gynaecologists, member of the National Commission of the Spanish Ministry of Health for Gamete Donors and member of the National Commission of the Spanish Ministry of Health, responsible of the National Biovigilance System.Degree in Medicine and Surgery, she specialised in Obstetrics and Gynaecology. According to the platform Research Gate, Dr López-Teijón appears among the top 10% of the most relevant researchers in the world. She divides her time between Institut Marquès’s General Management, the consultation and the Research and Development Project Team. Dr López-Teijón has been a pioneer in the study of male fertility and oestrogen disruptors. Also she created the first embryo adoption programme in 2004.

 

Recognised for her R&D work about the effects of music at the beginning of life: she is developing an important line of research about the effects of the musical micro-vibrations in the incubators during embryo development, thereby increasing the rate of in-vitro-fertilisation by 5%. In this field, she is the lead researcher of the study “Fetal facial expression in response to intravaginal music emission” the most downloaded study in Ultrasound, the journal of the British Medical Ultrasound Society (BMUS). She received the 2017 Ig Nobel Prize in Medicine for this work, the first in Obstetrics in the 27-year history of the prize (Harvard University, September 2017).

 

She is also the author of the blog “fertility-experiences.com“, with more than 850,000 readers. Her book “I want to get pregnant now!” published in English, Spanish and Italian has become an essential fertility guide.

Declan
Keane
CEO and Clinical Embryologist of the Repromed

Declan Keane has been working in the field of assisted reproduction since 1992 as a scientific and clinical embryologist. Following experience at reputable reproductive clinics in Ireland, USA (New York) and middle East, he founded the ReproMed clinic in Ireland in 2009, building on both his American experience and over 25 years of discipline expertise. The main philosophy of ReproMed was simple: to offer clients such services which Declan Keane would demand himself if he were its client. The boutique-style service concept succeeded and ReproMed soon became Ireland’s fastest growing assisted reproduction clinic with a huge impact on the provision of these services in Ireland. The commitment to always provide patients with the highest standard of treatment remains the main credo today.

Ladislav
Zgabur
FOUNDER AND SHAREHOLDER

MUDr. (MD) Ladislav Zgabur is a graduate of the Medical Faculty at Charles University and the Military Medical Research and Training Institute at Jan Purkyně University in Hradec Králové, field of General Medicine. He began working in health care management positions in 1990. He worked as the Administrative Director managing healthcare, the spa industry, and recreation for the Federal Ministry of the Interior of the Czechoslovak Federal Republic until 1992. He was one of the founders of the Health Insurance Company of the Ministry of the Interior and its first health director. Between 1995 and 2002, he acted in management positions at the Ministry of Health of the Czech Republic and at the VZP health insurance company. He began working on many private sector health care projects in 2002, and was chiefly involved in the consolidation of laboratories in the Czech Republic and Slovakia. He was also a major participant in the origin and development of the FUTURE LAB (now SYNLAB) Group and the AESKULAB Holding. In 2014, he prepared the FutureLife Group project, which he achieved in close cooperation with the HARTENBERG Company. He is currently involved in specialist management and other acquisitions for the FutureLife Company.

Board of
Directors

Jozef Janov
Jakub Čanda
Libor Němeček
István Szöke
Matěj Stejskal
Cathrin Petty

Company
Management

Jonáš Vokřál
Group Chief Operations Officer

Ing. Jonáš Vokřál, MBA has been the Group’s Chief Operating Officer since 2018, and since 2016 he has also been the REPROFIT Clinic Director. Formerly, he was part of REPROMEDA’s management and was involved in the audit of healthcare institutions at Pricewaterhouse Coopers. He graduated from the Faculty of Business and Economics of Mendel University in Brno, followed by a study in South Africa and MBA at the University of St. Francis in Chicago.

Štěpán Machač
Group Chief Medical Officer

MUDr. Štěpán Machač, Ph.D. was born in 1970. He graduated from the Palacký University of Medicine in Olomouc. From 1995 – 2003 he worked at the Gynaecology and Obstetrics Clinic of Faculty of Medicine and Dentistry at Palacký University Olomouc and started to deal with infertility treatment. In 2006, he obtained a Ph.D. degree, after defending his dissertation on ovarian hyper stimulation syndrome and congenital thrombophilia. In the years 2006 – 2014, he worked at the Reprofit International clinic as the lead IVF physician for foreign patients. Since 2014 he has been acting as a head of the IVF Clinic in Olomouc. In 2018 he was appointed as a Future Life CMO.

He has authored or co-authored more than 30 lectures and 40 articles in professional journals. In his work he focuses mainly on the issue of assisted reproduction, ovarian hyperstimulation syndrome and gamma donation.

Viktor Szabó
Group Chief Financial Officer

In June 2021, Mgr. Viktor Szabó, MBA, became the Chief Financial Officer of the group. He has extensive experience in financial management in healthcare. He managed a private chain of outpatient clinics for a long period, followed by the experience from the public healthcare sector, where he was responsible for financial restructuring of regional and state hospitals, including the highly specialized hospital Nemocnice na Homolce. Prior to healthcare career, he worked in corporate banking for Czech and French banks. He graduated from the Faculty of Financial Management at Charles University in Bratislava and obtained an MBA focused on healthcare.

Declan Keane
European Business Development Executive

Declan Keane has been working in the field of assisted reproduction since 1992 as a scientific and clinical embryologist. Following experience at reputable reproductive clinics in Ireland, USA (New York) and middle East, he founded the ReproMed clinic in Ireland in 2009, building on both his American experience and over 25 years of discipline expertise. The main philosophy of ReproMed was simple: to offer clients such services which Declan Keane would demand himself if he were its client. The boutique-style service concept succeeded and ReproMed soon became Ireland’s fastest growing assisted reproduction clinic with a huge impact on the provision of these services in Ireland. The commitment to always provide patients with the highest standard of treatment remains the main credo today.

Supervisory
Board

Ladislav Zgabur
Miroslav Janov
Anna Douchanova
Darshan Shah
Andreea Artemi
Josef Kováč
About us